Market Overview

UPDATE: Jefferies Lowers PT on Johnson & Johnson Following Global Pharma Review

Share:
Related JNJ
American Express, Johnson & Johnson, Square, Vale: Fast Money Picks For March 24
FDA Links Breast Implants To A Rare Form Of Cancer
Wall Street Breakfast: Art Of The Healthcare Deal (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Johnson & Johnson (NYSE: JNJ), but lowered the price target from $97.00 to $91.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Johnson & Johnson closed on Thursday at $83.68.

Latest Ratings for JNJ

DateFirmActionFromTo
Jan 2017Wells FargoDowngradesOutperformMarket Perform
Nov 2016BarclaysDowngradesOverweightEqual-Weight
Sep 2016JefferiesMaintainsHold

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (JNJ)

View Comments and Join the Discussion!